Atlantic Edge Private Wealth Management’s scPharmaceuticals SCPH Stock Holding History

Atlantic Edge Private Wealth Management’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-425	Closed	-$2.41K	–	598
2025 Q3	$2.41K	Hold	425	–	–	﹤0.01%	491
2025 Q2	$1.62K	Hold	425	–	–	﹤0.01%	476
2025 Q1	$1.12K	Hold	425	–	–	﹤0.01%	475
2024 Q4	$1.5K	Hold	425	–	–	﹤0.01%	450
2024 Q3	$1.94K	Hold	425	–	–	﹤0.01%	450
2024 Q2	$1.85K	Hold	425	–	–	﹤0.01%	431
2024 Q1	$2.13K	Hold	425	–	–	﹤0.01%	429
2023 Q4	$2.67K	Buy	+425	New	+$2.43K	﹤0.01%	404

Atlantic Edge Private Wealth Management's SCPH Position: Q4 2025 in Review

Atlantic Edge Private Wealth Management sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 425 shares — an estimated $2.41K sold.

Atlantic Edge Private Wealth Management first reported a position in SCPH in Q4 2023 and held it in 8 quarters. The position peaked at $2.67K in Q4 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

Atlantic Edge Private Wealth Management reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
Atlantic Edge Private Wealth Management sold 425 scPharmaceuticals shares in Q4 2025, an estimated $2.41K.
Atlantic Edge Private Wealth Management first reported a position in scPharmaceuticals in Q4 2023 and held it in 8 quarters.
Atlantic Edge Private Wealth Management's scPharmaceuticals position peaked at $2.67K in Q4 2023.
0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on Atlantic Edge Private Wealth Management's 13F filing for Q4 2025, filed 27 Jan 2026.